- Home
- CDLX vs TCRX Comparison
CDLX vs TCRX Comparison
Compare CDLX & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDLX
- TCRX
- Stock Information
- Founded
- CDLX 2008
- TCRX 2018
- Country
- CDLX United States
- TCRX United States
- Employees
- CDLX N/A
- TCRX N/A
- Industry
- CDLX Computer Software: Programming Data Processing
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CDLX Technology
- TCRX Health Care
- Exchange
- CDLX Nasdaq
- TCRX Nasdaq
- Market Cap
- CDLX 93.5M
- TCRX 91.7M
- IPO Year
- CDLX 2018
- TCRX 2021
- Fundamental
- Price
- CDLX $1.53
- TCRX $1.72
- Analyst Decision
- CDLX Hold
- TCRX Strong Buy
- Analyst Count
- CDLX 3
- TCRX 5
- Target Price
- CDLX $2.25
- TCRX $9.40
- AVG Volume (30 Days)
- CDLX 1.5M
- TCRX 218.2K
- Earning Date
- CDLX 11-05-2025
- TCRX 11-11-2025
- Dividend Yield
- CDLX N/A
- TCRX N/A
- EPS Growth
- CDLX N/A
- TCRX N/A
- EPS
- CDLX N/A
- TCRX N/A
- Revenue
- CDLX $266,201,000.00
- TCRX $6,961,000.00
- Revenue This Year
- CDLX N/A
- TCRX $255.18
- Revenue Next Year
- CDLX N/A
- TCRX N/A
- P/E Ratio
- CDLX N/A
- TCRX N/A
- Revenue Growth
- CDLX N/A
- TCRX N/A
- 52 Week Low
- CDLX $0.85
- TCRX $1.02
- 52 Week High
- CDLX $5.25
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- CDLX 56.23
- TCRX 43.84
- Support Level
- CDLX N/A
- TCRX $1.73
- Resistance Level
- CDLX $1.17
- TCRX $1.96
- Average True Range (ATR)
- CDLX 0.11
- TCRX 0.11
- MACD
- CDLX 0.04
- TCRX -0.02
- Stochastic Oscillator
- CDLX 97.46
- TCRX 22.58
About CDLX Cardlytics Inc.
Cardlytics Inc operates an advertising platform within financial institutions' digital channels, which include online, mobile, email, and various real-time notifications. The company operates through segments namely, Cardlytics platform in the U.S. and U.K. and the Bridg platform. The Cardlytics platform segment which generates key revenue, operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to the cloud-based customer-data platform and the delivery of professional services like implementation, onboarding, and technical support. The company receives maximum revenue from the United States.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.